Kornimate/medical-research-clean huggingface dataset:
prone patient positioning in reducing tumor motion and improving breathing reproduction in patients with lung cancer undergoing radiation therapy

Conditions: Lung Cancer

Summary: this clinical trial studies prone patient positioning in reducing tumor motion and improving breathing reproduction in patients with lung cancer undergoing radiation therapy. prone patient positioning during radiation therapy may help kill tumor cells without harming normal tissue.

primary objectives: i. quantify the three-dimensional tumor and normal tissue (thoracic and abdominal) motion, deformation and volume changes with the respiratory cycle during imaging in prone vs. supine positioning. ii. quantify the three-dimensional tumor and normal tissue (thoracic and abdominal) motion, deformation and volume changes with the respiratory cycle and alterations thereof during a radiotherapy series. outline: patients undergo one conventional computed tomography (ct) scan and one 4 dimensional ct (4d ct) scan in both supine and prone positioning before undergoing radiation therapy.

Eligibility criteria:
inclusion criteria: * measurable disease on the planning computed tomography (ct) scan * patients with lung cancer visible on fluoroscopic imaging or planning ct who are scheduled to receive external beam radiation treatment will be eligible for this study exclusion criteria: * patients requiring continuous supplemental oxygen due to the requirement of spirometry during all imaging studies * pregnant females
effect of anthracyclines and cyclophosphamide on cardiovascular responses

Conditions: Cardiotoxicity; Cardiovascular Disease; Neurovascular Disorder; Endothelial Disfunction; Breast Cancer

Summary: the present study aims to investigate the chronic effect of treatment with doxorubicin and cyclophosphamide on neurovascular control and blood pressure in women undergoing adjuvant treatment for breast cancer.

the development of new drugs and different adjuvant therapeutic regimens, based on the combination of anthracycline (a) and cyclophosphamide (c), have contributed greatly to improve survival rate in breast cancer patients. despite the clinical benefits of this therapy, ac treatment can cause cardiovascular acute and chronic changes. in a recent investigation, we observed that an acute ac chemotherapy session increases sympathetic nervous activity and blood pressure in patients with breast cancer. the present study aims to investigate the chronic effects of ac regimen on sympathetic nervous activity, peripheral vasoconstriction, endothelial microparticles and blood pressure, in women with breast cancer.

Eligibility criteria:
inclusion criteria: * diagnosis of stage ii-iii breast cancer * starting adjuvant chemotherapy exclusion criteria: * metastatic disease, * hypercholesterolemia, diabetes, * hypertension, * severe lymphedema, * organic disorders (renal failure, heart failure and chronic liver disease), * obesity (bmi\> 30) and, * who are under pharmacological treatment with statins, angiotensin-converting enzyme inhibitors, losartan potassium, beta blockers or antioxidants

Keywords: chemotherapy endothelial disfunction muscle sympathetic nerve activity blood pressure
surgical outcome of vitrectomy for myopic traction maculopathy in highly myopic eyes

Conditions: Maculopathy; High Myopia; Surgery

Summary: surgical outcome of vitrectomy for myopic traction maculopathy in highly myopic eyes was evaluated in each stage. efficacy of internal limiting membrane was also evaluated whether it may improve visual outcome.

surgical outcome of vitrectomy for myopic traction maculopathy in highly myopic eyes was evaluated in each stage of macular retinischisis, foveal detachment, or macular hole. efficacy of internal limiting membrane was also evaluated whether it may improve visual outcome.

Eligibility criteria:
inclusion criteria: * eyes with myopic traction maculopathy in highly myopic eyes with refractive errors ≤ -8.0 diopters and axial length ≥ 26.0 mm who underwent vitrectomy exclusion criteria: * eyes with follow-up less than a year

Keywords: myopic traction maculopathy vitrectomy internal limiting membrane retrospective, case control study
effects of intense aerobic exercise on the cerebrovascular reserve capacity in patients with hemodynamically relevant intra- and extracranial stenoses

Conditions: Stenosis

Summary: the purpose of this trial is to study the improvement of cerebral hemodynamics in high risk stroke patients with impaired cerebrovascular reserve (cvr) due to high grade stenosis of the internal carotid (ica) or middle cerebral artery (mca) by intense aerobic exercise (iaex).

the primary objective: intense aerobic exercise (24/8 weeks) improves cvr \> 20% measured by transcranial doppler (tcd) in patients with hemodynamic relevant intra- or extracranial stenoses by enhanced cerebral arterio- and angiogenesis. secondary objectives: intense aerobic exercise (24/8 weeks) leads to: * an increase of endothelial progenitor cell counts (epcs) * qualitative and quantitative changes of endothelial markers and cytokines representing the inflammatory activity of atherosclerosis and neovascularisation * an improvement in cognitive performance and quality of life (qol) * changes of the mean vessel size and of cerebral perfusion

Eligibility criteria:
inclusion criteria: * high-grade stenosis of the intra- or extracranial ica or the mca with ipsilateral impairment of the cvr capacity measured by tcd exclusion criteria: * continuous physical activity ≥ 60 min/week within the last 3 months * cerebral bleeding or ischaemic stroke \< 3 months * contraindications for spiro-ergometry, iaex, or mri

Keywords: chronic brain ischaemia stroke prevention exercise physical training chronic, extra- or intracranial stenoses of brain supplying arteries
study of bk1301 (dtap vaccine) as a booster in adolescents

Conditions: Diphtheria; Tetanus; Pertussis

Summary: this study is designed to assess the immunogenicity and safety of dtap vaccine (bk1301) as a booster dose in adolescents. the purposes of this study are as follows: * to confirm the non-inferiority of bk1301 to adsorbed diphtheria-tetanus combined toxoid (dt toxoid) with respect to booster responses for anti-diphtheria toxoid (anti-d) and anti-tetanus toxoid (anti-t) antibodies * to confirm that booster responses for anti-pertussis toxoid (anti-pt) and anti-filamentous hemagglutinin (anti-fha) antibodies are more than 80% of participants received bk1301


Eligibility criteria:
inclusion criteria: * age 11 or 12 years on the day of injection * received 3 or 4 doses of dtap vaccine exclusion criteria: * history of pertussis, diphtheria, tetanus * history of anaphylaxis to vaccine components * serious conditions or diseases of the heart, vein, blood, respiratory, hepar, kidney, digestive system, psychiatric or nervous system * transfused or received gamma globulin within 3 months, or received high-dose gamma globulin within 6 months before the day of injection

Keywords: diphtheria tetanus pertussis dtap vaccine adolescents
immune registry for bk in kidney transplant recipients

Conditions: BK Virus Infection; Kidney Transplant; Complications

Summary: kidney transplantation (kt) is the best treatment modality available to date for patients with advanced kidney disease and the success of kt is dependent on maintaining a selective intricate balance between the risk of rejection and infections in kt recipients. bk virus is an important clinical infection affecting the post-transplant outcomes in kt recipients. bk nephropathy can affect 8-15% of patients after kt causing acute kidney injury, increased risk of rejection and fibrosis leading to additional hospital stays, increasing overall health care cost burden, and in some cases graft loss. the exact pathogenesis and treatment options for bk nephropathy are not clearly understood. it is debatable whether bk nephropathy is a full fledge donor-derived infection or reactivation of the recipient's latent infection. irrespective of etiology, the common consensus is that treatment of bk virus infection depends on the selective restoration of host immune responses and balancing the risk of rejection vs worsening of infection.

as with other viral infections, adaptive immunity plays an essential role in the control of bk virus infection. previous studies have shown that humoral immunity doesn't prevent viral reactivation and cellular responses including cd4+ and cd8+ t cells play a crucial role in containing viral replication. researchers have investigated the role of reconstitution of bk-specific t cell immunity kt recipients with overall low immunological risk populations showing that pre and post-transplant bk virus-specific cellular responses can be used as an important tool to identify kt recipients at increased risk of developing bk virus infection in the first year post-transplant. we plan to understand the role of adaptive immunity (cellular and humoral interplay) in a cohort with at least 50% of high immunological kt recipients with predominantly retransplant candidates, highly sensitized recipients with calculated panel reactive antibodies \> 40 %, positive crossmatch or history of prior desensitization therapies. the aim includes the sequential demonstration of immunogenesis processes that are specific to the bk virus in individuals who experience bk viremia and undergo various treatment approaches such as immunosuppression reduction and immune enhancement through intravenous immunoglobulins (ivig).

Eligibility criteria:
inclusion criteria: * adult (\>18 years old) male and female, deceased donor kt recipients * will include single organ transplants. * each participant must also have recently been diagnosed with bk viremia. * in addition to the aforementioned inclusion criteria, each participant in the sub-study must also have recently been diagnosed with bk viremia or have difficult-to-treat bkv \> 3 logs (bkv log does not decrease by more than 1 log copy/ml drop on second per protocol lab). exclusion criteria: * prisoners will not be included in the study * multi-organ transplants and pregnant women

Keywords: immune registry bk in kidney transplant recipients
ultrasound guided block of stellate ganglion versus greater occipital nerve in resistant migraine and correlation to calcitonin gene related peptide

Conditions: Migraine

Summary: to investigate the efficacy of ultrasound guided stellate ganglion block in chronic resistant migraine patients in comparison to greater occipital nerve block correlating its effect to serum cgrp level.

40 patients diagnosed with chronic resistant migraine to 2 anti-migraine drugs for 3 months will be evaluated for inclusion and exclusion. eligible patients with resistance or intolerability to 2 drugs or more will be classified into two groups by using simple randomization methods through using a computer-generated random number sequence. each group will contain 20 patients one group will undergo ultrasound guided bilateral greater occipital nerve block and the other group will undergo ultrasound guided bilateral stellate ganglion block

Eligibility criteria:
inclusion criteria: * individuals diagnosed with chronic resistant migraine after using or intolerability to 2 or more of anti-migraine drugs for at least 3 months exclusion criteria: * patients with a space-occupying lesion. * coagulation disorders. * systemic or local infection and drug allergies.

Keywords: occipital nerve block stellate ganglion block migraine
immunotherapy-related crp kinetics in early and metastatic triple-negative breast cancer

Conditions: TNBC - Triple-Negative Breast Cancer

Summary: ick-breast is a prospective, multicentric, non-interventional investigator-initiated trial (iit) that aims to investigate the prognostic value of crp kinetics in early and advanced or metastatic triple negative breast cancer (tnbc) under immune checkpoint inhibitor (ici) therapy on pathological complete response (pcr) and event-free survival in early tnbc patients, and objective response rate (orr), progression-free survival (pfs) and overall survival (os) in advanced or metastatic tnbc.

immunotherapy, which involves activating the body's immune system for cancer treatment, has already been widely incorporated into the standard care of breast cancer patients with early and metastatic triple-negative breast cancer (tnbc). this study aims to investigate how inflammatory markers such as c-reactive protein (crp) change during and after immunotherapy. study findings from other tumor types (kidney, lung, bladder) suggest that immunotherapy is particularly effective when a mild inflammatory response is triggered in the body. the investigators want to examine this using crp measurement. crp measurement can easily be integrated into clinical routine as it only requires a blood sample. and since the patients already need a blood draw for chemotherapy, crp measurement can be performed directly from the blood sample. the goal of this prospective study is to determine whether changes in crp levels in the blood can predict the disease progression or response to immunotherapy.

Eligibility criteria:
inclusion criteria: * women ≥ 18 years of age * histologically proven early or advanced or metastatic invasive breast cancer irrespective of therapy line * er-negative and progesterone receptor (pr)-negative and human epidermal growth factor receptor 2 (her2)-negative (ihc 0-2+, fluorescence in situ hybridization (fish) neg.) * patients with advanced or metastatic disease must be programmed cell death ligand 1 (pd-l1)-positive (ic ≥ 1 or combined positive score (cps) ≥ 10) in the experimental group * planned ici therapy in combination with chemotherapy in the experimental group * written informed consent into ick-breast exclusion criteria: * er-positive or pr-positive * her2-positive (ihc 2+, fish pos or ihc 3+) * any systemic breast cancer therapy before inclusion into the trial for early breast cancer patients * any ici therapy before inclusion into the trial * pregnant or lactating patients * inadequate general condition (not fit for chemotherapy)
therapeutic drug monitoring of beta-lactams and renal hyperclearance in patients admitted to intensive care for acute brain injury

Conditions: Critical Illness; Brain Injuries

Summary: augmented renal clearance (arc), defined as a supraphysiological increase in renal function, is frequently observed in critically ill patients, particularly those with acute brain injury. arc complicates the management of renally eliminated drugs, specifically beta-lactam antibiotics, by enhancing drug clearance and thereby increasing the risk of underdosing and therapeutic failure. although pharmacological therapeutic drug monitoring (tdm) is recommended to optimize dosing, it remains limited by issues of accessibility, highlighting the need for alternative approaches to identify at-risk patients and adjust dosing based on renal function. early identification of patients at risk for subtherapeutic beta-lactam plasma concentrations could enable timely dose adjustments. a combined assessment of renal function and beta-lactam tdm could enhance our understanding of the kinetics of both parameters. these data may support the development of predictive models capable of proposing individualized dosing regimens based on renal function. optimizing beta-lactam plasma concentrations in this patient population could improve infection management and potentially enhance clinical outcomes.


Eligibility criteria:
inclusion criteria: * adult patients (≥18 years old) * admitted to the intensive care unit for acute brain injury * exhibiting augmented renal clearance (arc), defined by a urinary creatinine clearance (clcru) greater than 130 ml/min/1.73 m² on at least one measurement * receiving therapeutic drug monitoring (tdm)-guided treatment with one of the following beta-lactam antibiotics: amoxicillin/clavulanic acid, cefotaxime, piperacillin/tazobactam, cefepime, or meropenem * affiliated with or benefiting from a health insurance scheme exclusion criteria: * estimated life expectancy \<24 hours * patients who have expressed opposition to study participation * patients under legal protection (guardianship, curatorship, or court protection) * patients currently in an exclusion period determined by participation in another study * patients already enrolled in a study that precludes concurrent participation in an observational study

Keywords: beta-lactams renal clearance therapeutic drug monitoring
immune resolution after staphylococcus aureus bacteremia

Conditions: Immune Response To Sepsis; Staphylococcus Aureus Infection

Summary: the purpose of this study is to determine how monocyte hla-dr and other markers of immune function change with time in patients with and without prior immune dysfunction who survive sepsis from staphylococcus aureus bacteremia. we hypothesize that patients with prior immune dysfunction will have greater reductions in hla-dr and other markers of immune function after an episode of sepsis than people who do not have prior immune dysfunction.


Eligibility criteria:
inclusion criteria: * at least one blood culture positive for s. aureus * patients aged ≥18 years * at least two of four systemic inflammatory response syndrome (sirs) criteria on the day of positive blood cultures. sirs criteria are: * body temperature less than 36°c(96.8°f) or greater than 38°c(100.4°f) * heart rate greater than 90 beats per minute * tachypnea (high respiratory rate), with greater than 20 breaths per minute; or, an arterial partial pressure of carbon dioxide less than 32 mmhg * wbc less than 4000 cells/mm³ (4 x 109 cells/l) or greater than 12,000 cells/mm³ (12 x 109 cells/l); or the presence of greater than 10% immature neutrophils (band forms) exclusion criteria: * sequential organ failure assessment (sofa) score \> 12 on day of positive blood cultures * survival expected to be \< 7 days from positive blood cultures

Keywords: immunosuppressed sepsis staphylococcus aureus bacteremia hla-dr
a study of sunvozertinib combined with anlotinib in local advanced or metastatic non-small cell lung cancer

Conditions: NSCLC

Summary: the study will evaluate the efficacy and safety of treatment with sunvozertinib in combination with anlotinib in patients whose disease has progressed following first-line egfr-tkis treatment.


Eligibility criteria:
inclusion criteria: 1. capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol. 2. pathologically confirmed non-squamous nsclc. locally advanced or metastatic nsclc 3. egfr sensitive mutations confirmed by accredited local laboratories， including 19del、l858r and t790m。 4. intolerant or refuses, or not suitable for systemic chemotherapy. 5. progressed after egfr-tki targeted therapy or are intolerant to standard treatment; if carry t790m mutation, need to be treated with osimertinib or other third-generation egfr-tki. 6. world health organization performance status of 0 to 1 7. life expectancy \>12 weeks at day 1. 8. at least 1 lesion to be measured 9. females must be using highly effective contraceptive measures, and must have a negative pregnancy test prior to start of dosing if of childbearing potential, or must have evidence of non-childbearing potential by fulfilling criteria at screening. 10. male patients must be willing to use barrier contraception exclusion criteria: 1. any known ret rearrangement, braf v600e mutation, ntrk fusion, met ex14 skip mutation, met amplification (defined as tissue detection gcn ≥ 5 by ngs) 2. any concurrent and/or other active malignancy within 2 years 3. major surgery within 4 weeks of the first dose of ip 4. any unresolved toxicities from prior therapy. 5. past medical history of ild (interstitial lung disease)/pneumonitis, drug-induced ild/pneumonitis, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ild/pneumonitis 6. any evidence of severe or uncontrolled systemic diseases. 7. any of the following cardiac criteria: i) mean resting qtc \>470 msec ii) any clinically important abnormalities in rhythm, conduction, or morphology of resting electrocardiogram iii) any factors that increase the risk of qtc prolongation or risk of arrhythmic events 8. refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of sunvozertinib and anlotinib 9. severe allergies to sunvozertinib and anlotinib
a clinical study of chinese domestic surgical robot

Conditions: Gallstone; Cholecystitis

Summary: this is a prospective, multi-center, randomized, single-blind, parallel-controlled clinical trial to evaluate the safety and efficacy of the chinese domestic endoscopic instrument control system in clinical treatment.

to evaluate the safety and efficacy of the chinese domestic endoscopic instrument control system in clinical treatment.this clinical trial is a prospective, multi-center, randomized, single-blind, parallel-controlled study. the system used in the experimental group is the endoscopic instrument control system developed by wego surgical robot co., ltd., and the system used in the control group is the da vinci endoscopic instrument control system developed by intuitive surgical. before patients are enrolled in this clinical study, the researchers will do a detailed screening of the subjects based on the inclusion criteria and the exclusion criteria to determine if the patients are appropriate for the clinical study. patients who meet the conditions of the study will be required to sign an informed consent form. then they will be randomly assigned to the experimental group or the control group. to evaluate the primary outcome measures and secondary outcome measures and to observe the incidence of organ and vascular injury. finally, we evaluate the safety and efficacy of the test product through the comparison of the data obtained from the experimental group and the control group during the treatment.

Eligibility criteria:
inclusion criteria: 1. 18-65 years old, male or female 2 .american society of anesthesiologists (asa): level 1, level 2 or level 3 3. bmi 18-30kg/m2 4. benign gallbladder diseases such as acute or chronic cholecystitis, gallstones and polypoid lesions of gallbladder 5. subjects or their legal representatives/guardians voluntarily participate in clinical trials and have signed informed consent form exclusion criteria: 1. participating in any other clinical trial within 30 days before signing the informed consent form 2. pregnancy or lactation 3. with a history of epilepsy or psychosis 4. with a history of previous operations at related sites 5. severe cardiovascular and cerebrovascular diseases with new york grade iii-iv cardiac function or pulmonary insufficiency that can't tolerate the operation 6. severe liver and kidney insufficiency such as cirrhosis and renal failure 7. acute cholecystitis lasting for more than 72 hours, acute cholecystitis with severe complications such as cholecystitis, gangrene, perforation, etc., and gallbladder thickness thicker than 10 mm 8. acute cholangitis, gallstone with acute pancreatitis, primary common bile duct stones, intrahepatic bile duct stones and obstructive jaundice 9. gallbladder cancer or protuberant lesions are suspected to be cancerous 10. severe allergic constitution and suspected or identified addicts to alcohol or drugs 11. abdominal infection, peritonitis, diaphragmatic hernia, severe systemic infection or metastatic diseases 12. other situations that researchers consider it inappropriate to participate in this clinical trial